Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Abstract: Mounting bracket assemblies including first, second and third bracket members. The first bracket member includes first and second mounting surface portions. The first mounting surface portion engaging a suspension component. The second mounting surface portion defining a receiving zone for receiving a vehicle structure and is disposed along a first side of a first central plane of the receiving zone. A second bracket member includes first and second contact surface portions. The second bracket member is disposed along a second side of the first central plane and along a first side of a second central plane of the receiving zone. A third bracket member includes third and fourth contact surface portions. The third bracket member is disposed along the second side of the first central plane and along a second side of the second central plane. Suspension systems, kits and methods are also included.

Abstract: Disclosed herein is a composition comprising a mutant peanut (Arachis hypogaea) Ara h 6 polypeptide, a mutant Ara h 2 polypeptide, or a combination thereof in a pharmaceutically acceptable carrier, wherein the mutant Ara h 6 polypeptide and/or mutant Ara h 2 polypeptide has a reduced IgE response in a subject with a peanut allergy compared to wildtype Ara h 6 or Ara h 2 polypeptide. Also disclosed is a method for desensitizing or tolerizing a subject with a peanut allergy, comprising administering to the subject the mutant peanut Ara h 6 and/or Ara h 2 polypeptides disclosed herein. Also disclosed is a method for monitoring progress for the disclosed therapeutic methods.

Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Abstract: Mounting bracket assemblies including first, second and third bracket members. The first bracket member includes first and second mounting surface portions. The first mounting surface portion engaging a suspension component. The second mounting surface portion defining a receiving zone for receiving a vehicle structure and is disposed along a first side of a first central plane of the receiving zone. A second bracket member includes first and second contact surface portions. The second bracket member is disposed along a second side of the first central plane and along a first side of a second central plane of the receiving zone. A third bracket member includes third and fourth contact surface portions. The third bracket member is disposed along the second side of the first central plane and along a second side of the second central plane. Suspension systems, kits and methods are also included.

Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the detection, treatment and prevention of allergies, such as those to peanut allergens.

Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Abstract: A method for preparing an abradable panel for a rub strip of a fan case of a gas turbine engine includes forming an abradable material into a plurality of panels each comprising an abradable structure; curing the abradable material in the plurality of panels; and installing the plurality of panels into the fan case. The panels can be cured and assembled into a fully assembled rubstrip, and then the assembled rubstrip can be installed into the fan case.

Abstract: The present disclosure is directed to human monoclonal IgE antibodies, and IgG antibodies engineered therefrom. Such engineered antibodies can be used to blunt pathologic IgE responses in subjects, such as in the treatment or prevention of allergies.

Abstract: An abradable material for a rub strip of a gas turbine engine component includes a polymer matrix, and an organic or inorganic filler distributed through the matrix, wherein the abradable material has a compression spring rate profile including: less than 50,000 lb/in at ?65° F., less than 35,000 lb/in at room temperature, and less than 35,000 lb/in at 200° F.

Abstract: Mounting bracket assemblies including a base bracket and a clamp. The base bracket includes a base bracket wall with a base wall portion having a first surface portion and a second surface portion. The base bracket is positioned along an existing jounce bumper mount of a vehicle with the first surface portion engaging a distal edge of the jounce bumper mount. The clamp is the base bracket and extends peripherally along a side wall portion of the jounce bumper mount in abutting engagement with an outer peripheral surface portion thereof and coextensively therewith. Suspension systems, mounting bracket kits and methods of assembling a mounting bracket assembly are also included.

Abstract: The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-?-1, 3-galactose, a known red meat allergen, and methods for use thereof.